Efficacy of Adalimumab Biosimilars in Managing Perianal Fistula in Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis.

This meta-analysis supports the efficacy and safety of adalimumab biosimilars in managing perianal fistulas in moderate to severe CD. The findings suggest that adalimumab biosimilars are effective and safe in managing perianal fistulas in Crohn's disease, but further direct comparative studies with originator adalimumab are needed to establish equivalence. Further large-scale RCTs are recommended to confirm these results and establish long-term safety data.